JP2023544406A5 - - Google Patents
Info
- Publication number
- JP2023544406A5 JP2023544406A5 JP2023520432A JP2023520432A JP2023544406A5 JP 2023544406 A5 JP2023544406 A5 JP 2023544406A5 JP 2023520432 A JP2023520432 A JP 2023520432A JP 2023520432 A JP2023520432 A JP 2023520432A JP 2023544406 A5 JP2023544406 A5 JP 2023544406A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- dose
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087668P | 2020-10-05 | 2020-10-05 | |
| US63/087,668 | 2020-10-05 | ||
| US202063109719P | 2020-11-04 | 2020-11-04 | |
| US63/109,719 | 2020-11-04 | ||
| US202163144048P | 2021-02-01 | 2021-02-01 | |
| US63/144,048 | 2021-02-01 | ||
| US202163157922P | 2021-03-08 | 2021-03-08 | |
| US63/157,922 | 2021-03-08 | ||
| EP21315151 | 2021-08-31 | ||
| EP21315151.7 | 2021-08-31 | ||
| PCT/US2021/053328 WO2022076289A1 (en) | 2020-10-05 | 2021-10-04 | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544406A JP2023544406A (ja) | 2023-10-23 |
| JP2023544406A5 true JP2023544406A5 (enExample) | 2024-10-11 |
Family
ID=78414079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520432A Pending JP2023544406A (ja) | 2020-10-05 | 2021-10-04 | Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220169739A1 (enExample) |
| EP (1) | EP4225436A1 (enExample) |
| JP (1) | JP2023544406A (enExample) |
| KR (1) | KR20230082650A (enExample) |
| AU (1) | AU2021357078A1 (enExample) |
| BR (1) | BR112023004020A2 (enExample) |
| CA (1) | CA3194111A1 (enExample) |
| MX (1) | MX2023003942A (enExample) |
| WO (1) | WO2022076289A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102502640B1 (ko) | 2012-08-21 | 2023-02-23 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| KR102872485B1 (ko) | 2016-09-01 | 2025-10-20 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
| KR20220034878A (ko) | 2019-07-16 | 2022-03-18 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| WO2024011251A1 (en) * | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| WO2025026821A1 (en) * | 2023-07-28 | 2025-02-06 | Novartis Ag | New uses of omalizumab |
| TW202620051A (zh) * | 2024-09-18 | 2026-05-16 | 香港商香港康乃德生物醫藥有限公司 | 介白素-4受體α抗體的使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| US11034768B2 (en) * | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-10-04 US US17/493,101 patent/US20220169739A1/en active Pending
- 2021-10-04 KR KR1020237014950A patent/KR20230082650A/ko active Pending
- 2021-10-04 AU AU2021357078A patent/AU2021357078A1/en active Pending
- 2021-10-04 JP JP2023520432A patent/JP2023544406A/ja active Pending
- 2021-10-04 CA CA3194111A patent/CA3194111A1/en active Pending
- 2021-10-04 WO PCT/US2021/053328 patent/WO2022076289A1/en not_active Ceased
- 2021-10-04 MX MX2023003942A patent/MX2023003942A/es unknown
- 2021-10-04 BR BR112023004020A patent/BR112023004020A2/pt unknown
- 2021-10-04 EP EP21799152.0A patent/EP4225436A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ji et al. | T-helper cells and their cytokines in pathogenesis and treatment of asthma | |
| Hamelmann et al. | IL‐5‐induced airway eosinophilia–the key to asthma? | |
| Casale | Biologics and biomarkers for asthma, urticaria, and nasal polyposis | |
| Ritchie et al. | Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety | |
| Wang et al. | Paroxetine alleviates T lymphocyte activation and infiltration to joints of collagen-induced arthritis | |
| JP2022169718A5 (enExample) | ||
| Shanmugasundaram et al. | Phenotype and Functionality of CD 4+ and CD 8+ T Cells in the Upper Reproductive Tract of Healthy Premenopausal Women | |
| US20110166148A1 (en) | Treatment of inflammation using alpha 7 receptor-binding cholinergic agonists | |
| JP2020513404A5 (enExample) | ||
| Noda et al. | Vascular adhesion protein-1 blockade suppresses choroidal neovascularization | |
| JP2020516647A5 (enExample) | ||
| JP2013544235A (ja) | 肺機能を改善する治療法 | |
| JP2010520197A (ja) | 免疫性障害の処置のための組合せ治療 | |
| CN110431240B (zh) | 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 | |
| CN104870013A (zh) | 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 | |
| TW201904991A (zh) | Btla同效劑抗體及其用途 | |
| KR20190038919A (ko) | 항-nkg2d 항체로 크론병을 치료하는 방법 | |
| CN106573056A (zh) | 用于诊断和治疗炎症性肠病的方法和组合物 | |
| Wu et al. | Anticardiolipin and/or anti-β2-glycoprotein-I antibodies are associated with adverse IVF outcomes | |
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| Petri et al. | Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice | |
| Llewellyn-Smith et al. | Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412 | |
| Ezekwe et al. | Biologics in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis | |
| Wu et al. | The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis | |
| EP1030865A2 (en) | Th2 CELL DEPLETION; COMPOSITIONS; METHODS |